What is Rage Biotech?
Rage Biotech operates at the intersection of advanced molecular biology and therapeutic innovation. The company is dedicated to developing novel inhibitors that target the Receptor for Advanced Glycation End-products (RAGE), a critical pathway in the progression of chronic inflammatory diseases. By leveraging sophisticated RNA-targeting and therapeutic peptide technologies, the firm addresses significant unmet medical needs in patients suffering from conditions such as COPD, severe asthma, and cystic fibrosis. As a research-driven entity, Rage Biotech distinguishes itself through a focus on high-impact, science-led solutions that aim to improve patient outcomes on a global scale. Its market position is bolstered by a robust intellectual property pipeline and a commitment to addressing the underlying mechanisms of inflammation that drive chronic respiratory and systemic illnesses.
How much funding has Rage Biotech raised?
Rage Biotech has raised a total of $32.7M across 2 funding rounds:
Seed
$3.7M
Series A
$29M
Seed (2021): $3.7M, investors not publicly disclosed
Series A (2025): $29M led by IP Group, Hostplus, and Monash University
Key Investors in Rage Biotech
IP Group
IP Group Australia is an investment firm focused on transforming innovative ideas into impactful businesses, particularly in the realm of science and technology.
Hostplus
Hostplus is a prominent Australian superannuation fund that provides institutional backing to high-growth ventures and infrastructure projects.
Monash University
Monash University is a leading research institution that fosters high-impact innovation and commercialization of academic breakthroughs.
What's next for Rage Biotech?
Looking ahead, the infusion of capital from this Series A round will be instrumental in scaling Rage Biotech's operational capabilities and advancing its lead candidates through preclinical and clinical evaluation. The company is expected to prioritize the expansion of its research team and the optimization of its therapeutic peptide manufacturing processes. Furthermore, the strategic alignment with institutional investors provides not only financial stability but also access to a broader ecosystem of scientific expertise and commercial networks. As the firm transitions from a development-stage entity to a clinical-stage organization, the focus will remain on validating the efficacy of its RAGE inhibitors in human trials. This progression is essential for establishing long-term value and achieving the company's mission of transforming the standard of care for patients with difficult-to-treat inflammatory diseases.
See full Rage Biotech company page
